Journal article

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Abstract:: Background: Casirivimab and imdevimab are non-competing monoclonal antibodies that bind to two different sites on the receptor binding domain of the SARS-CoV-2 spike glycoprotein, blocking viral entry into host cells. We aimed to evaluate the efficacy and safety of casirivimab and imdevimab administered in combination in patients admitted to hospital with COVID-19.

Methods: RECOVERY is a randomised, controlled, open-label platform trial comparing s...
Expand abstract
Collapse abstract

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Landray, M., Horby, P., Mafham, M., Peto, L., Campbell, M., Pessoa-Amorim, G., Spata, E., Staplin, N., Emberson, J., & Haynes, R. (2022). Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet, 399(10325), 665–676.

MLA Style

Landray, M., et al. “Casirivimab and Imdevimab in Patients Admitted to Hospital with COVID-19 (RECOVERY): a Randomised, Controlled, Open-Label, Platform Trial.” Lancet, vol. 399, no. 10325, Elsevier, 2022, pp. 665–76.

Chicago Style

Landray, M, P Horby, M Mafham, L Peto, M Campbell, G Pessoa-Amorim, E Spata, N Staplin, J Emberson, and R Haynes. 2022. “Casirivimab and Imdevimab in Patients Admitted to Hospital with COVID-19 (RECOVERY): a Randomised, Controlled, Open-Label, Platform Trial.” Lancet 399 (10325): 665–76.
Share
Print

Access Document

Files:: Landray_et_al_2022_casirivimab_and_imdevimab.pdf

(Preview, Version of record, 1.0MB, Terms of use)

Publisher copy:: 10.1016/S0140-6736(22)00163-5

Authors

+ Landray, M More by this author

Institution:: University of Oxford
Division:: MSD
Department:: Nuffield Department of Population Health
Sub department:: Clinical Trial Service Unit
Role:: Author

+ Horby, P More by this author

Role:: Author

+ Mafham, M More by this author

Role:: Author

+ Peto, L More by this author

Role:: Author

+ Campbell, M More by this author

Role:: Author

More authors...

Contributors

+ RECOVERY Collaborative Group

Role:: Contributor

Publisher:: Elsevier
Journal:: Lancet More from this journal
Volume:: 399
Issue:: 10325
Pages:: 665-676
Publication date:: 2022-02-12
Acceptance date:: 2021-12-14
DOI:: 10.1016/S0140-6736(22)00163-5
EISSN:: 1474-547X
ISSN:: 0140-6736

Language:: English
Keywords:: FFR
Pubs id:: 1225614
Local pid:: pubs:1225614
Deposit date:: 2021-12-16

Terms of use

Copyright holder:: Landray et al
Copyright date:: 2022
Rights statement:: © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Licence:: CC Attribution (CC BY)

Views and Downloads

About views and downloads

If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP